Cargando…

Improving Lurasidone Hydrochloride’s Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin

The biopharmaceutical classification system groups low-solubility drugs into two groups: II and IV, with high and low permeability, respectively. Most of the new drugs developed for common pathologies present solubility issues. This is the case of lurasidone hydrochloride—a drug used for the treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamboa-Arancibia, María Elena, Caro, Nelson, Gamboa, Alexander, Morales, Javier Octavio, González Casanova, Jorge Enrique, Rojas Gómez, Diana Marcela, Miranda-Rojas, Sebastián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861442/
https://www.ncbi.nlm.nih.gov/pubmed/36678861
http://dx.doi.org/10.3390/pharmaceutics15010232
_version_ 1784874842489618432
author Gamboa-Arancibia, María Elena
Caro, Nelson
Gamboa, Alexander
Morales, Javier Octavio
González Casanova, Jorge Enrique
Rojas Gómez, Diana Marcela
Miranda-Rojas, Sebastián
author_facet Gamboa-Arancibia, María Elena
Caro, Nelson
Gamboa, Alexander
Morales, Javier Octavio
González Casanova, Jorge Enrique
Rojas Gómez, Diana Marcela
Miranda-Rojas, Sebastián
author_sort Gamboa-Arancibia, María Elena
collection PubMed
description The biopharmaceutical classification system groups low-solubility drugs into two groups: II and IV, with high and low permeability, respectively. Most of the new drugs developed for common pathologies present solubility issues. This is the case of lurasidone hydrochloride—a drug used for the treatment of schizophrenia and bipolar depression. Likewise, the stability problems of some drugs limit the possibility of preparing them in liquid pharmaceutical forms where hydrolysis and oxidation reactions can be favored. Lurasidone hydrochloride presents the isoindole-1,3-dione ring, which is highly susceptible to alkaline hydrolysis, and the benzisothiazole ring, which is susceptible to a lesser extent to oxidation. Herein, we propose to study the increase in the solubility and stability of lurasidone hydrochloride by the formation of higher-order inclusion complexes with hydroxypropyl-β-cyclodextrin. Several stoichiometric relationships were studied at between 0.5 and 3 hydroxypropyl-β-cyclodextrin molecules per drug molecule. The obtained products were characterized, and their solubility and stability were assessed. According to the obtained results, the formation of inclusion complexes dramatically increased the solubility of the drug, and this increased with the increase in the inclusion ratio. This was associated with the loss of crystalline state of the drug, which was in an amorphous state according to infrared spectroscopy, calorimetry, and X-ray analysis. This was also correlated with the stabilization of lurasidone by the cyclodextrin inhibiting its recrystallization. Phase solubility,(1)H-NMR, and docking computational characterization suggested that the main stoichiometric ratio was 1:1; however, we cannot rule out a 1:2 ratio, where a second cyclodextrin molecule could bind through the isoindole-1,3-dione ring, improving its stability as well. Finally, we can conclude that the formation of higher-order inclusion complexes of lurasidone with hydroxypropyl-β-cyclodextrin is a successful strategy to increase the solubility and stability of the drug.
format Online
Article
Text
id pubmed-9861442
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98614422023-01-22 Improving Lurasidone Hydrochloride’s Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin Gamboa-Arancibia, María Elena Caro, Nelson Gamboa, Alexander Morales, Javier Octavio González Casanova, Jorge Enrique Rojas Gómez, Diana Marcela Miranda-Rojas, Sebastián Pharmaceutics Article The biopharmaceutical classification system groups low-solubility drugs into two groups: II and IV, with high and low permeability, respectively. Most of the new drugs developed for common pathologies present solubility issues. This is the case of lurasidone hydrochloride—a drug used for the treatment of schizophrenia and bipolar depression. Likewise, the stability problems of some drugs limit the possibility of preparing them in liquid pharmaceutical forms where hydrolysis and oxidation reactions can be favored. Lurasidone hydrochloride presents the isoindole-1,3-dione ring, which is highly susceptible to alkaline hydrolysis, and the benzisothiazole ring, which is susceptible to a lesser extent to oxidation. Herein, we propose to study the increase in the solubility and stability of lurasidone hydrochloride by the formation of higher-order inclusion complexes with hydroxypropyl-β-cyclodextrin. Several stoichiometric relationships were studied at between 0.5 and 3 hydroxypropyl-β-cyclodextrin molecules per drug molecule. The obtained products were characterized, and their solubility and stability were assessed. According to the obtained results, the formation of inclusion complexes dramatically increased the solubility of the drug, and this increased with the increase in the inclusion ratio. This was associated with the loss of crystalline state of the drug, which was in an amorphous state according to infrared spectroscopy, calorimetry, and X-ray analysis. This was also correlated with the stabilization of lurasidone by the cyclodextrin inhibiting its recrystallization. Phase solubility,(1)H-NMR, and docking computational characterization suggested that the main stoichiometric ratio was 1:1; however, we cannot rule out a 1:2 ratio, where a second cyclodextrin molecule could bind through the isoindole-1,3-dione ring, improving its stability as well. Finally, we can conclude that the formation of higher-order inclusion complexes of lurasidone with hydroxypropyl-β-cyclodextrin is a successful strategy to increase the solubility and stability of the drug. MDPI 2023-01-10 /pmc/articles/PMC9861442/ /pubmed/36678861 http://dx.doi.org/10.3390/pharmaceutics15010232 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gamboa-Arancibia, María Elena
Caro, Nelson
Gamboa, Alexander
Morales, Javier Octavio
González Casanova, Jorge Enrique
Rojas Gómez, Diana Marcela
Miranda-Rojas, Sebastián
Improving Lurasidone Hydrochloride’s Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin
title Improving Lurasidone Hydrochloride’s Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin
title_full Improving Lurasidone Hydrochloride’s Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin
title_fullStr Improving Lurasidone Hydrochloride’s Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin
title_full_unstemmed Improving Lurasidone Hydrochloride’s Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin
title_short Improving Lurasidone Hydrochloride’s Solubility and Stability by Higher-Order Complex Formation with Hydroxypropyl-β-cyclodextrin
title_sort improving lurasidone hydrochloride’s solubility and stability by higher-order complex formation with hydroxypropyl-β-cyclodextrin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861442/
https://www.ncbi.nlm.nih.gov/pubmed/36678861
http://dx.doi.org/10.3390/pharmaceutics15010232
work_keys_str_mv AT gamboaarancibiamariaelena improvinglurasidonehydrochloridessolubilityandstabilitybyhigherordercomplexformationwithhydroxypropylbcyclodextrin
AT caronelson improvinglurasidonehydrochloridessolubilityandstabilitybyhigherordercomplexformationwithhydroxypropylbcyclodextrin
AT gamboaalexander improvinglurasidonehydrochloridessolubilityandstabilitybyhigherordercomplexformationwithhydroxypropylbcyclodextrin
AT moralesjavieroctavio improvinglurasidonehydrochloridessolubilityandstabilitybyhigherordercomplexformationwithhydroxypropylbcyclodextrin
AT gonzalezcasanovajorgeenrique improvinglurasidonehydrochloridessolubilityandstabilitybyhigherordercomplexformationwithhydroxypropylbcyclodextrin
AT rojasgomezdianamarcela improvinglurasidonehydrochloridessolubilityandstabilitybyhigherordercomplexformationwithhydroxypropylbcyclodextrin
AT mirandarojassebastian improvinglurasidonehydrochloridessolubilityandstabilitybyhigherordercomplexformationwithhydroxypropylbcyclodextrin